* Please carefully read the instructions before use

Core tests® COVID-19 Ag Test

Format: Cassette

Specimen: nasopharyngeal swab specimens

INTENDED USE

COVID-19 Ag Test is the chromatographic immunoassay test used for qualitative detection of the COVID-19 antigen in human nasopharyngeal swab specimens

INTRODUCTION

CoV is mainly transmitted through direct contact with secretions or through aerosols and droplets. Evidence suggests transmission via fecal-oral route. 7 kinds of HCoVs caused human,s respiratory diseases are found by now: HCoV-229E, CoV-OC43, SARS-CoV HCoV-NL63, HCoV-HKU1, MERS-CoV and 2019-nCoV which are the serious pathogens for human's respiratory diseases. Its clinical manifestation are fever, enervate and systemic symptom, with dry cough, difficult breathing etc. and it may aggravate to severe pneumonia, respiratory failure, acute respiratory distress syndrome ,septic shock, multiple organ failure, severe acid-base metabolic disorders etc and even life threatening rapidly.

The target antigen detected by the Coretests® COVID-19 Ag Test is N protein. The mutant site of currently known mutant strains such as UK mutant strain (B.1.1.7), South African mutant (501.V2), Brazil mutant (P.1) and Delta variant are not at the identification site of the Coretests® COVID-19 Ag test. It has been verified that the new coronavirus antigens of UK mutant strain (B.1.1.7), South African mutant (501.V2), Brazil mutant (P.1) and Delta variant can be detected by the Coretests® COVID-19 Ag test

PRINCIPLE

This test kit uses COVID-19 monoclonal antibody and goat anti-mouse IgG polyclonal antibodies that are respectively immobilized on a nitrocellulose membrane. It uses colloidal gold to label sufficient COVID-19 monoclonal antibody. Using nano-colloidal gold technology and applying highly specific antibody-antigen reaction and immunochromatographic analysis technology principle.
When testing, the novel coronavirus antigen in the sample combined

with the colloidal gold-labeled COVID-19 monoclonal antibody to form a complex, which was then combined with the COVID-19 monoclonal antibody coated in the T line during chromatography, at this time there is one red line in the T area .When the samples do not contain novel coronavirus antigen, colloidal gold-labeled COVID-19 monoclonal antibody cannot combined with COVID-19 monoclonal antibody in the T line region, so there is no red colored line in the T area. Regardless of the presence of novel coronavirus antigen in the sample, a red line will form in the quality control area (C). The red line appears in the quality control area (C) serves as: 1.verification that sufficient volume is added 2 that sees figure. verification that sufficient volume is added. 2.that proper flow is obtained 3, and as a control for the reagents

MATERIALS PROVIDED

Coretests® COVID-19 Ag Test contains the following items to perform the assay (Packing: 1test/kit or 25 tests/kit):

- COVID-19 Ag Test cassette
- 2. Instruction for use
- 3 Sample collection tube
- Nasopharyngeal swab
- Sample processing solution

MATERIALS REQUIRED BUT NOT PROVIDED

Clock or Timer

WARNING AND PRECAUTIONS

- Read instruction for use carefully before performing this test.
- For in vitro diagnostic use and professional use only Do not use the test cassette beyond the expiration date
- The test cassette should remain in the sealed pouch until use. Do not use the test cassette if the pouch is damaged or the seal
- Do not reuse the cassette.
- Treat and properly handle the specimens and used cassette as if they were potentially infectious. Dispose all specimens and used cassettes in a proper bio-hazard container. The handling and disposal of the hazardous materials should follow local, national or regional regulations.
- There should be no eating, drinking or smoking where specimens are being handled.
- Do not mix or interchange different specimens.
- Wear disposable gloves, lab coat and eye protection while handling potentially infectious material and performing the assay. Wash hands thoroughly afterwards
- 10. Clean spills thoroughly using an appropriate disinfectant

SPECIMEN PREPARATION

- The collection method of nasopharyngeal swab is shown in Figure 4 to 7.
- Sample processing:
 - Figure 1.Insert the sample collection tube into the hole of provided box. Make sure that the tube is standing firm and reaches the bottom of the workstation.
 - Figure 2. Unscrew the top of sample processing solution bottle. Figure 3. Add 0.3 mL (all solutions in the buffer bottle) of the

sample processing solution into the collection tube.

Figure 8. Insert the swab in collection tube to the bottom, rotate and squeeze the swab 10 times while pressing the head against the bottom and side of the collection tube.

Figure 9. Leave the swab in the collection tube for 1 minute.

Figure 10. Rotate and squeeze the tube several times with fingers from outside of the tube to unwater the swab. Remove the swab.

Screw the cap of collection tube. Figure 11.

Figure 12. Shake and mix the retained solution well. The retained solution will be tested with COVID-19 Ag test.


Note:

- Please use swab for specimen colletion.
- It is highly recommended to collect specimen with wearing a pair of safety gloves to avoid contamination.
- Do not touch the tip(specimen collection area) of the swab.
- Collect sample as soon as after onset of symptoms.
- It is recommended to treat the sample immediately after collection. The sample can be stored at 2°C~8°C for 72 hours, and it needs to be frozen at -20°C for long-term storage, avoiding repeated freezing and thawing.

6



Insert the sample collection tube into the hole of provided box. Make sure that the tube is standing firm and reaches the bottom of the workstation.










Place the swab into one of patient's nostrils until reaches the posterior nasopharynx.










Remove a nasopharyngeal swab from the pouch.








TEST PROCEDURE



Read the instruction first prior to testing. Bring the pouched test to room temperature prior to testing. Do not open the pouch until ready to begin testing.

- Remove the test from the sealed pouch. Lay it on a flat, clean and dry surface.
- Reverse the sample collection tube, and add 2-3 drops (about 75~100 µL) of test sample by squeezing the collection solution tube into the sample well
- Read results within 10-15 minutes.

INTERPRETATION OF RESULTS



Positive:Control line and T line appear in the show window. **Negative:**Only one line appears in Control area, no line appears in T

Invalid:If no line appears in the control area, the test results are invalid regardless of the presence or absence of line in the test area. The direction may not been followed correctly or the test may be deteriorated. It is recommended that repeat the test using a new device. If the problem persist, please stop to use the product and contact local distributor.

STORAGE AND STABILITY

Storage: store at 2~40°C Shelf life: 24 months.

LIMITATION OF THE TEST

This kit is a clinical auxiliary test product. Any sample with a positive test result should be further confirmed by other methods.

PERFORMANCE CHARACTERISTICS

1. Limit of Detection (Analytical Sensitivity)

The Coretests® COVID-19 Ag Test LOD in natural nasopharyngeal swab matrix was confirmed as 22.5 TCID₅₀/ml.

2. Analytic Specificity

Results demonstrated that Coretests® COVID-19 Ag Test has no significant cross-reactivity with the seromarkers listed following:

Potential Cross-Reactant	Test Concentration
Adenovirus	1.0 x 10⁵ TCID50/ml
Human metapneumovirus (hMPV)	1.0 x 10 ⁵ TCID₅₀/ml
Rhinovirus	1.0 x 10⁵ PFU/ml
Enterovirus/Coxsackievirus B4	1.0 x 10⁵ TCID₅₀/ml
Human coronavirus OC43	1.0 x 10⁵ TCID₅₀/ml
Human coronavirus 229E	1.0 x 10⁵ TCID50/ml
Human coronavirus NL63	1.0 x 10⁵ TCID₅₀/ml
Human parainfluenza virus 1	1.0 x 10 ⁵ TCID₅₀/ml
Human parainfluenza virus 2	1.0 x 10⁵ TCID₅₀/ml
Human parainfluenza virus 3	1.0 x 10⁵ TCID₅₀/ml
Human parainfluenza virus 4	1.0 x 10⁵ TCID₅₀/ml
Influenza A	1.0 x 10⁵ TCID50/ml
Influenza B	1.0 x 10⁵ TCID50/ml
Respiratory Syncytial Virus A	1.0 x 10⁵ PFU/ml
Bordetella pertussis	1.0 x 10 ⁶ cells/ml
Chlamydia pneumoniae	1.0 x 10 ⁶ IFU/ml
Haemophilus influenzae	1.0 x 10 ⁶ cells/ml
Legionella pnuemophila	1.0 x 10 ⁶ cells/ml
Mycoplasma pneumoniae	1.0 x 10 ⁶ U/ml
Streptococcus pneumoniae	1.0 x 10 ⁶ cells/ml
Streptococcus pyogenes (group A)	1.0 x 10 ⁶ cells/ml
Mycobacterium tuberculosis	1.0 x 10 ⁶ cells/ml
Staphylococcus aureus	1.0 x 10 ⁶ org/ml
Staphylococcus epidermidis	1.0 x 10 ⁶ org/ml
Pooled human nasal wash	N/A
Candida albicans	1.0 x 10 ⁶ cells/ml
	Adenovirus Human metapneumovirus (hMPV) Rhinovirus Enterovirus/Coxsackievirus B4 Human coronavirus OC43 Human coronavirus OC43 Human coronavirus NL63 Human parainfluenza virus 1 Human parainfluenza virus 2 Human parainfluenza virus 3 Human parainfluenza virus 4 Influenza A Influenza B Respiratory Syncytial Virus A Bordetella pertussis Chlamydia pneumoniae Haemophilus influenzae Legionella pnuemophila Mycoplasma pneumoniae Streptococcus progenes (group A) Mycobacterium tuberculosis Staphylococcus eureus Staphylococcus epidermidis Pooled human nasal wash

3. Interference

The following substances and conditions were found not to interfere with the test. List of potentially interfering compounds and concentrations tested are as follows:

Substance Active Ingredient		Concentration
F	Mucin	2% w/v
Endogenous	Whole Blood	1% v/v
OTC Nasal Drops Phenylephrine		15% v/v
OTC Nasal Gel	Sodium Chloride (i.e. NeilMed)	5% v/v
OTC Nasal Spray 1	Cromolyn	15% v/v
OTC Nasal Spray 2 Oxymetazoline		15% v/v
OTC Nasal Spray 3	Fluconazole	5% w/v
Throat Lozenge	Benzocaine, Menthol	0.15% w/v
OTC Homeopathic Nasal Spray 1	Galphimia glauca, Sabadilla,	20% v/v
OTC Homeopathic Nasal Spray 2	Zincum gluconium (i.e., Zicam)	5% w/v
OTC Homeopathic Nasal Spray 3	Alkalol	10% v/v

OTC Homeopathic Nasal Spray 4	Fluticasone Propionate	5% v/v
Sore Throat Phenol Spray	Phenol	15% v/v
Anti-viral Drug	Tamiflu (Oseltamivir Phosphate)	0.5% w/v
Antibiotic, Nasal Ointment	Mupirocin	0.25% w/v
Antibacterial, Systemic	Tobramycin	0.0004% w/v

DIAGNOSTIC SENSITIVITY AND SPECIFIC

A study using a total 655 nasopharyngeal swab samples was conducted. Test results of Coretests® COVID-19 Ag test were compared with nucleic acid detection test. The diagnostic sensitivity and specificity of the test results are given as below:

Reference		Results of Nucleic acid detection test		Total Results
		Positive	Negative	- Fotal F toodito
Results of Coretests COVID-19 Ag test	Positive	152	2	154
	Negative	3	498	501
Tota	al Results	155	500	655

Results gave sensitivity is 98.1% (152/155), specificity is 99.6% (498/500), and a total agreement of 99.2%(650/655).

PRECAUTIONS

- This kit is used for one-time in vitro testing. The same kit cannot be reused.
- This kit is suitable for qualitative detection of human nasopharyngeal swab samples.
- The experimental environment should be protected from wind, and experiments should not be performed in an excessively high temperature, high humidity, or excessively dry environment.
- 4. The test samples should be regarded as infectious agents and the operation should be in accordance with the infectious disease laboratory operating rules. After using this kit, the waste should be disposed according to the expected waste management system.
- Do not use after the expiration date.
- Before using this kit, you must read this manual carefully and strictly control the reaction time. If you do not follow the instructions, you will get inaccurate results.
- The results of samples are closely related to the methods of sample collection. Incorrect sample collection may result in negative results.
- Do not use turbid contaminated samples for testing.
- This kit will show negative results under the following conditions, when the new coronavirus antigen titer in the sample is below the minimum detection limit of the kit.
- 10. Incorrect sampling method may lead to inaccurate test results.

INDEX OF SYMBOLS

(2)		Do not re-use	LOT	Batch code
IVD		In vitro diagnostic medical device	Σ	Use-by date
rc. 1	nc	Store at 2-40°C	[]i	Consult instructions for use
EC R	EP	Authorized representative in the European Community	***	Manufacturer

MANUFACTURER CONTACT INFORMATION



Core Technology Co.,Ltd.

Room 100, C Building, No.29 Life Park Rd., Changping District, Beijing 102206, China

EC REP

Wellkang Ltd.

Enterprise Hub, NW Business Complex,

1 Beraghmore Rd. Derry, BT48 8SE, N. Ireland, UK

Doc No. IFU-COVID Ag/05-C Ver.1.2

Eff.Date: Nov.2020